Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Dry Powder Inhaler Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to :
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 1nhaler Ltd
- Acorda Therapeutics Inc
- Advent Pharmaceuticals Pty Ltd
- Aespira Ltd.
- AKELA Pharma Inc. (Formerly LAB International, Inc.) (Inactive)
- Bayer AG
- Belhaven Biopharma Inc
- Cambridge Healthcare Innovations Ltd
- Creare LLC
- DMK Pharmaceuticals Corp
- Glenmark Pharmaceuticals Ltd
- GSK plc
- Hovione Technology Ltd
- Iconovo AB
- Lupin Pharmaceuticals Inc
- MannKind Corp
- Monash University
- Nektar Therapeutics
- Ology Bioservices Inc
- OPKO Health Inc
- OtiTopic Inc
- Phargentis SA
- PureIMS BV
- Quench Medical Inc
- Receptor Life Sciences Inc
- Respira Therapeutics Inc
- Respirent Pharmaceuticals Co Ltd
- Sandoz International GmbH
- Sheffield Hallam University
- Shin Nippon Biomedical Laboratories Ltd
- Spyryx Biosciences Inc (Inactive)
- Syntara Ltd
- Teva Pharmaceutical Industries Ltd
- Transpire Bio Inc
- United Therapeutics Corp
- University of Kansas
- University of Sydney
- University of Texas Medical Branch at Galveston
- Vectura Group Plc
- Verona Pharma Plc
- Virginia Commonwealth University